These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11908201)

  • 1. Non-myeloblative induction of mixed hematopoietic chimerism: application to transplantation tolerance and hematologic malignancies in experimental and clinical studies.
    Sykes M; Spitzer TR
    Cancer Treat Res; 2002; 110():79-99. PubMed ID: 11908201
    [No Abstract]   [Full Text] [Related]  

  • 2. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect.
    Sprangers B; Van Wijmeersch B; Fevery S; Waer M; Billiau AD
    Nat Clin Pract Oncol; 2007 Jul; 4(7):404-14. PubMed ID: 17597705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hurdles to the induction of tolerogenic mixed chimerism.
    Pilat N; Klaus C; Schwaiger E; Wekerle T
    Transplantation; 2009 May; 87(9 Suppl):S79-84. PubMed ID: 19424016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Present status and future prospects in reduced intensity stem cell transplantation].
    Takaue Y
    Nihon Naika Gakkai Zasshi; 2005 Jul; 94(7):1421-7. PubMed ID: 16097602
    [No Abstract]   [Full Text] [Related]  

  • 7. Donor lymphocyte infusions after reduced intensity conditioning allogeneic transplantation: what we need to know.
    Marks DI; Parker A; Robinson SP
    Blood; 2004 Jul; 104(1):295-6. PubMed ID: 15208210
    [No Abstract]   [Full Text] [Related]  

  • 8. Hematopoietic stem cell transplantation and cellular therapy.
    Kolb HJ
    HLA; 2017 May; 89(5):267-277. PubMed ID: 28371460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outpatient allografting in hematologic malignancies and nonmalignant disorders--applying lessons learned in the canine model to humans.
    Maris M; Storb R
    Cancer Treat Res; 2002; 110():149-75. PubMed ID: 11908197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation.
    Saito TI; Rubio MT; Sykes M
    Exp Hematol; 2006 Sep; 34(9):1271-7. PubMed ID: 16939820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stem cells enhance the induction of mixed chimerism and tolerance to rat hind-limb allografts after bone marrow transplantation.
    Pan H; Zhao K; Wang L; Zheng Y; Zhang G; Mai H; Han Y; Yang L; Guo S
    J Surg Res; 2010 May; 160(2):315-24. PubMed ID: 19524257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed allogeneic chimerism to induce tolerance to solid organ and cellular grafts.
    Exner BG; Acholonu IN; Bergheim M; Mueller YM; Ildstad ST
    Acta Haematol; 1999; 101(2):78-81. PubMed ID: 10202237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
    Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
    Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimerism-based tolerance in organ transplantation: preclinical and clinical studies.
    Oura T; Cosimi AB; Kawai T
    Clin Exp Immunol; 2017 Aug; 189(2):190-196. PubMed ID: 28369830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the clinical importance of privileged sites.
    van Rood JJ
    Hum Immunol; 2002 Oct; 63(10):799-804. PubMed ID: 12368031
    [No Abstract]   [Full Text] [Related]  

  • 16. Chimerism as an important marker in post-transplant monitoring chimerism monitoring.
    Cechova H; Leontovycova M; Pavlatova L
    HLA; 2018 Dec; 92 Suppl 2():60-63. PubMed ID: 30362266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
    Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST
    J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT.
    Or-Geva N; Reisner Y
    Bone Marrow Transplant; 2015 Jun; 50 Suppl 2():S14-20. PubMed ID: 26039201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerance and chimerism after renal and hematopoietic-cell transplantation.
    Scandling JD; Busque S; Dejbakhsh-Jones S; Benike C; Millan MT; Shizuru JA; Hoppe RT; Lowsky R; Engleman EG; Strober S
    N Engl J Med; 2008 Jan; 358(4):362-8. PubMed ID: 18216356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8(+) T-cell count on day + 14 as a predictor of acute graft-versus-host disease.
    Petersen SL; Madsen HO; Ryder LP; Svejgaard A; Masmas TN; Dickmeiss E; Heilmann C; Vindeløv LL
    Biol Blood Marrow Transplant; 2004 May; 10(5):337-46. PubMed ID: 15111933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.